Sign In
NewsRadar

Search Press
Looking for press releases of a particular company? Enter company name (or keyword) here.

   


Affimed appoints Chief Business Officer


Heidelberg, Germany – June 05, 2008 – Affimed Therapeutics AG, a biopharmaceutical company focused on the development of antibody therapeutics, today announced that it has appointed Volker Lang, Ph.D., as its Chief Business Officer.

Dr. Lang joins Affimed from Scil Technology where he was Vice President of Corporate Development. At Scil Technology, he was responsible for the commercial development of a portfolio of regenerative medicine products including an eye-catching deal with Pfizer earlier this year. In his 16 years experience in the biotechnology sector, spanning basic research, industrial R&D, Business Development & Licensing, and commercial operations & management, Dr. Lang contributed significantly in the scientific development and commercialization of biological agents for industrial and healthcare applications.

“Dr. Lang’s has broad scientific knowledge and extensive experience in the sector of Business Development as well as his dynamic approach will be of great benefit to Affimed,” said Rolf H. Günther, MD PhD, Chief Executive Officer of Affimed. “This is particularly important as our product portfolio is now entering a very interesting phase with several milestones coming up”.

“Affimed has a strong track record in antibody research and a team assembled to translate that into commercial success,“ said Dr. Volker Lang, the new Chief Business Officer of Affimed. “I am excited and feel privileged to be joining the company at this pivotal stage.”

Dr. Lang replaces Gavin D Clark who has been working as VP Business Development for the last 2 years. Mr Clark is a founding partner at Procela Partners Limited and he will be continuing to consult for a number of early stage Biotech and Discovery Science based companies both in EU and US.

Dr. Lang combines a background as scientist and project manager with extensive experience in the commercialisation of biotechnology products. He has also gained considerable CMC/Production experience in his previous positions. Dr. Lang received his Ph.D. from the Technical University of Brunswick. After that he worked as an industry scientist and project manager with UCB-Celltech and Fresenius-Kabi, respectively. He joined Cosmix GmbH, Brunswick as Head of Business Development, and later Chief Operating Officer. Following Cosmix and prior to joining Scil Technology he was Vice President of Business Development at Pieris Proteolab AG.

About Affimed Therapeutics AG
Affimed is a private biopharmaceutical company based in Heidelberg, Germany specialising in the development of recombinant antibodies - the fastest growing segment of the pharmaceutical industry. Affimed was founded in May 2000 by Professor Melvyn Little as a spin-off of his group »Recombinant Antibodies« at the German Cancer Research Centre in Heidelberg. By utilizing its broad portfolio of proprietary, in-house technology platforms together with crucial enabling freedom-to-operate licenses, the company has been able to establish a pre-clinical product pipeline of promising novel product candidates mainly for indications in oncology and autoimmune diseases. To learn more about Affimed please visit www.affimed.com.

Further Information:

Dr Rolf Günther
Chief Executive Officer
Affimed Therapeutics AG
t: +49 (0)6221 65307 20
e: r.guenther@affimed.com

Dr. Douglas Pretsell
Account Director, Munich Bureau Chief
College Hill Life Sciences
t : +49 (0)89 57 00 18 06
e: douglas.pretsell@collegehill.com


Publisher Contact Information:

Affimed Therapeutics AG
+49 (0)6221 65307 20
r.guenther@affimed.com

Company profile of Affimed Therapeutics AG
Past press releases of Affimed Therapeutics AG.

Data


25,720
Tech investments
From our Online Data Service
16,652
VC-backed companies
From our Radar


Recent Deals


DATEAMOUNTSECTOR
May 17€4.0MBiopharmaceuticals
May 16€15.0MPayment software
May 16€4.0MInternet services
May 16€80.0MConsumer electronics
May 16€6.3MImaging
May 16€13.0MInternet services
May 16€34.5MBiotechnology

For information on Europe's most extensive database on technology funding click here!

Events



Press Releases


Apr 29
Nethone
nethone raised over $1 million from innovation nest

Oct 1
The Link App
the link app launches version 2.0

Mar 29
Addex Therapeutics
addex sucessfully raises chf40 million in capital increase

Jan 2
Urban Jungle
urban jungle raises £1m in seed funding to build tech-enabled home ...

Aug 17
Komed Health
komed health closes seed financing round





About usContact usLegal Information
Copyright © 1999-2019
Emerging Technology Research Europe Inc. All rights reserved.